Table 2. Univariate and multivariate analyses for OS and PFS.
| N=108 | Univariate | Multivariate* | ||
|---|---|---|---|---|
| OS (HR, 95%CI) | PFS (HR, 95%CI) | OS (HR, 95%CI) | PFS (HR, 95%CI) | |
| Age (≥ 60 vs. < 60 year) | 2.456 (1.340-4.504) | 1.846 (1.094-3.115) | 2.230 (1.192-4.170) | 2.278 (1.320-3.931) |
| HSCT vs. non-HSCT | 1.993 (1.021-3.888) | - - | - - | - - |
| Progressive MDS vs. non-progressive MDS) |
- - | 2.190 (1.127-4.258) | - - | 1.819 (1.418-2.332) |
| GATA1/GATA2 mutation | 2.703 (1.048-6.970) | - - | 3.714 (1.341-10.287) | - - |
| TP53 mutation | 3.160 (1.117-59.320) | - - | - - | - - |
| DNMT3A mutation | 3.106 (1.211-7.971) | - - | 2.842 (1.070-7.547) | - - |
| RUNX1 mutation | - - | 2.208 (1.136-4.293) | - - | - - |
| KRAS/NRAS mutation | - - | 2.678 (1.137-6.307) | 3.525 (1.288-9.650) | - - |
| SRSF2 mutation | - - | 2.870 (1.225-6.722) | - - | - - |
| TET2 mutation | - - | 2.248 (1.103-10.060) | - - | - - |
| IDH1/IDH2 mutation | - - | - - | - - | 0.273 (0.081-0.919) |
| ≥ 2 mutations vs. <2 mutations |
- - | - - | - - | 3.364 (1.428-7.925) |
*Multiple variables were selected for the Cox proportional hazard model: age (≥ 60 vs. < 60 year), white blood cell count, platelet count, hemoglobin, bone marrow blast, IPSS-R, administered treatment therapy (HSCT vs. non-HSCT), diagnosis (progressive MDS vs. non-progressive MDS) and mutations (including mutations with frequency ≥ 5% and those involved in epigenetic modification: RUNX1, BCOR/BCORL1, U2AF1, KRAS/NRAS, GATA1/GATA2, ETV6, NOTCH1/NOTCH2, STAG2, SETBP1, SRSF2, TP53, CEBPA, ASXL1, TET2, DNMT3A, IDH1/IDH2, EZH2, SETD2, KDM6A, KMT2A. And when analyzing “ ≥ 2 mutations vs. <2 mutations”, the mutation variables were removed.
Abbreviations: OS, overall survival; PFS, progression-free survival.